Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Stuttgart - Delayed Quote EUR

Oryzon Genomics S.A. (ORN.SG)

Compare

2.8200

-0.0750

(-2.59%)

As of 12:11:35 PM GMT+1. Market Open.

ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting

All resolutions were approved MADRID, Spain and CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A., a clinical-stage biopharmaceutical company focused on epigenetics for the development of therapies for diseases with significant unmet medical needs, today announced the results of voting at the Extraordinary General Shareholders' Meeting held today in Madrid. A total of 24,030,812 of the Company's issued and outstanding ordinary shares (representing 36.5312% of the share cap

GlobeNewswire 2 hours ago

ORYZF
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024

Reshaping its Board of Directors at the upcoming Shareholders’ meeting with the aim of enhancing U.S. outreachPreparations for PORTICO-2 Phase III trial with vafidemstat in agitation/aggression in Borderline Personality Disorder ongoing Final data from REIMAGINE proof-of-concept Phase IIa trial published in Psychiatry and Clinical NeurosciencesContinues to enroll patients in Phase IIb EVOLUTION trial with vafidemstat in schizophreniaFirst patients dosed in Investigator-initiated Phase I study of

GlobeNewswire 19 hours ago

ORYZF
ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences

The Phase IIa study REIMAGINE evaluated the safety and preliminary efficacy of vafidemstat in agitation/aggression in borderline personality disorder (BPD), attention-deficit/hyperactivity disorder (ADHD) and autistic spectrum disorder (ASD) Vafidemstat demonstrated a relevant clinical benefit in reducing agitation/aggression across all studied patient populations Data was seminal to start further clinical development in BPDAfter an informative Phase IIb in BPD and FDA EoPII meeting, preparation

GlobeNewswire 14 days ago

ORYZF
ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders’ Meeting

Aimed at enhancing U.S. outreach, investor relations, corporate dialogue, and business development (BD) capabilities MADRID and CAMBRIDGE, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces significant changes to its Board of Directors at the upcoming Shareholders' Meeting, scheduled for February 28. Four new memb

GlobeNewswire last month

ORYZF
ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome

Exploring the combination with azacitidineStudy led by Medical College of Wisconsin MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the first patient has been dosed in an investigator-initiated Phase I dose-finding trial of iadademstat, Oryzon’s potent and selective LSD1 inhibit

GlobeNewswire last month

ORYZF
ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor

MADRID, Spain and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, is pleased to announce the appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor. Dr. Beaurang has over 25 years of experience in biotechnology focusing on corporate strategy, business development, oncology, immunology

GlobeNewswire last month

ORYZF
ORYZON Announces First Patient Dosed in NCI-Sponsored Iadademstat in Combination With Venetoclax and Azacitidine Clinical Trial in First Line Acute Myeloid Leukemia

Study conducted under the CRADA agreement between NCI and Oryzon MADRID, Spain and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the first patient has been dosed in a Phase I dose-finding clinical trial of iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in combination with ven

GlobeNewswire last month

ORYZF
ORYZON to Provide Corporate Progress Updates at Several Events in January-February

8th Sachs Annual Neuroscience Innovation Forum14th Annual LifeSci Advisors Corporate Access EventInvest Securities BioMed Forum 2025MidCap Events Frankfurt 2025Bio-Neuroscience 2025 MADRID and CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate p

GlobeNewswire last month

ORYZF
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat

“Decision to grant” communication in RussiaMADRID and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the Russian Patent Office has issued a “Decision to grant” communication for Oryzon’s Russian patent application RU2021130172, titled “Methods of treating borderline personality disorder”.

GlobeNewswire 2 months ago

ORYZF
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024

Final data from PORTICO, global Phase IIb vafidemstat trial in BPD, presented at the 37th ECNP annual conference in SeptemberCompany moving forward with PORTICO-2 Phase III trial preparations following positive feedback from End-of-Phase II meeting with the FDA Company continues to strengthen IP position for vafidemstat with additional “intention to grant” communications First cohort dosed in Investigator-initiated Phase Ib study of iadademstat with venetoclax and azacitidine in first-line AMLRe

GlobeNewswire 4 months ago

ORYZF
ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder

FDA’s feedback supports the initiation of the Phase III trialAgitation-Aggression in Borderline Personality Disorder (BPD) acknowledged as a possible therapeutic indicationOryzon may use STAXI-2 Trait anger as a primary efficacy endpoint for PORTICO-2Currently no FDA-approved treatments for BPD Company to host conference call and live webcast today at 09:00 am EDT (15:00 pm CET) MADRID and CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a

GlobeNewswire 4 months ago

ORYZF
ORYZON Presents the Final Data From PORTICO, a Global Phase IIb Vafidemstat Trial in Borderline Personality Disorder (BPD), at the European College of Neuropsychopharmacology (ECNP) Congress

Strong improvement in State-Trait Anger Expression Inventory 2 (STAXI-2) Trait Anger, a measure of agitation and aggression, at Weeks 8–12 compared to previous top line data; nominal statistical significance now of p = 0.0071Improvement in Borderline Evaluation of Severity (BEST), an overall measure of BPD disease severity, at Weeks 8–12 compared to previous top line data; nominal statistical significance now of p = 0.0260Vafidemstat showed favorable results over placebo in all primary and secon

GlobeNewswire 5 months ago

ORYZF
ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder

From the European Patent OfficeMADRID and CAMBRIDGE, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the European Patent Office (EPO) has issued an “intention to grant” communication for Oryzon’s European patent application EP20712565.9 entitled “Methods of treating borderline personality disorder”

GlobeNewswire 5 months ago

ORYZF
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid Leukemia

Exploring the triple combination with venetoclax and azacitidineStudy sponsored by Oregon Health & Science University (OHSU) MADRID and CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the first patient has been dosed in an investigator-initiated Phase Ib dose-finding trial of iadademstat,

GlobeNewswire 5 months ago

ORYZF
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat with Additional “Decision to Grant” Communications

In Australia, Malaysia and Mexico MADRID and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it has received additional “Decision to grant” communications for important patents relating vafidemstat, Oryzon’s LSD1 inhibitor in clinical development for the treatment of psychiatric disorders

GlobeNewswire 5 months ago

ORYZF
ORYZON to Provide Corporate Progress Updates at Several Events in September

German Fall Conference 2024European College of Neuropsychopharmacology (ECNP) congress 2024Sachs Annual Biotech in Europe Forum 2024 MADRID, Spain and CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in

GlobeNewswire 5 months ago

ORYZF
ORYZON reports financial results and corporate update for half-year ending June 30, 2024

Company granted an End-of-Phase II meeting with the FDA to discuss plans for a registrational Phase III trial with vafidemstat in Borderline Personality Disorder (BPD)Final data from PORTICO, global Phase IIb vafidemstat trial in BPD, scheduled as an oral presentation at the 37th ECNP annual conference in SeptemberCompany continues to strengthen IP position in CNS with formal notices of intention to grant two patent applications in Japan covering the use of vafidemstat to treat BPD and Attention

GlobeNewswire 6 months ago

ORYZF
ORYZON Receives “Decision to grant” for Two Important Patents for Vafidemstat in Japan

For the treatment of Borderline Personality Disorder (BPD) and Attention Deficit Hyperactivity disorder (ADHD)MADRID and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it has received “Decision to grant” communications from the Japanese Patent Office (JPO) for two Japanese patent applicat

GlobeNewswire 7 months ago

ORYZF
ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders

All resolutions were approvedAdditional resolution to increase capital for up to 100 million euros approved42.6867% of the issued shares represented MADRID and CAMBRIDGE, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, announced the voting results from its Annual General Meeting of Shareholders held today in Madrid. A

GlobeNewswire 7 months ago

ORYZF
ORYZON Announces Presentation of Final Data From PORTICO, Vafidemstat’s Global Phase IIb Trial in Borderline Personality Disorder, at the 37th ECNP Annual Conference

Selected for oral presentationConference will be held in Milan on September 21-23 MADRID and CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today announced that it will present final data from its Phase IIb PORTICO trial, which investigated the efficacy of vafidemstat in the treatment of Borderline Personalit

GlobeNewswire 7 months ago

ORYZF

Performance Overview

Return	ORN.SG	IBEX 35...
YTD	+92.10%	+15.69%
1-Year	+51.29%	+31.97%
3-Year	+0.53%	+57.28%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Oryzon Genomics S.A. (ORN.SG)

ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024

ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences

ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders’ Meeting

ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome

ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor

ORYZON Announces First Patient Dosed in NCI-Sponsored Iadademstat in Combination With Venetoclax and Azacitidine Clinical Trial in First Line Acute Myeloid Leukemia

ORYZON to Provide Corporate Progress Updates at Several Events in January-February

ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat

ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024

ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder

ORYZON Presents the Final Data From PORTICO, a Global Phase IIb Vafidemstat Trial in Borderline Personality Disorder (BPD), at the European College of Neuropsychopharmacology (ECNP) Congress

ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder

ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid Leukemia

ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat with Additional “Decision to Grant” Communications

ORYZON to Provide Corporate Progress Updates at Several Events in September

ORYZON reports financial results and corporate update for half-year ending June 30, 2024

ORYZON Receives “Decision to grant” for Two Important Patents for Vafidemstat in Japan

ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders

ORYZON Announces Presentation of Final Data From PORTICO, Vafidemstat’s Global Phase IIb Trial in Borderline Personality Disorder, at the 37th ECNP Annual Conference

Performance Overview